You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
|
|---|---|
| Published in |
Cardiovascular Diabetology, January 2014
|
| DOI | 10.1186/1475-2840-13-102 |
| Pubmed ID | |
| Authors |
Bernard Zinman, Silvio E Inzucchi, John M Lachin, Christoph Wanner, Roberto Ferrari, David Fitchett, Erich Bluhmki, Stefan Hantel, Joan Kempthorne-Rawson, Jennifer Newman, Odd Johansen, Hans-Juergen Woerle, Uli C Broedl |
| Abstract |
Evidence concerning the importance of glucose lowering in the prevention of cardiovascular (CV) outcomes remains controversial. Given the multi-faceted pathogenesis of atherosclerosis in diabetes, it is likely that any intervention to mitigate this risk must address CV risk factors beyond glycemia alone. The SGLT-2 inhibitor empagliflozin improves glucose control, body weight and blood pressure when used as monotherapy or add-on to other antihyperglycemic agents in patients with type 2 diabetes. The aim of the ongoing EMPA-REG OUTCOME™ trial is to determine the long-term CV safety of empagliflozin, as well as investigating potential benefits on macro-/microvascular outcomes. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 20% |
| Unknown | 4 | 80% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 80% |
| Scientists | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 319 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 2 | <1% |
| Spain | 1 | <1% |
| Denmark | 1 | <1% |
| Germany | 1 | <1% |
| Unknown | 314 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 43 | 13% |
| Student > Master | 35 | 11% |
| Other | 34 | 11% |
| Student > Ph. D. Student | 28 | 9% |
| Student > Bachelor | 26 | 8% |
| Other | 60 | 19% |
| Unknown | 93 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 139 | 44% |
| Pharmacology, Toxicology and Pharmaceutical Science | 23 | 7% |
| Nursing and Health Professions | 15 | 5% |
| Agricultural and Biological Sciences | 11 | 3% |
| Biochemistry, Genetics and Molecular Biology | 10 | 3% |
| Other | 19 | 6% |
| Unknown | 102 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 38. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 March 2021.
All research outputs
#987,108
of 23,846,647 outputs
Outputs from Cardiovascular Diabetology
#40
of 1,464 outputs
Outputs of similar age
#11,285
of 312,380 outputs
Outputs of similar age from Cardiovascular Diabetology
#1
of 36 outputs
Altmetric has tracked 23,846,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,464 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 312,380 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.